The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer
Less than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSC) survive more than five years post-diagnosis but those who have an exceptionally long survival could provide insights into tumor biology and therapeutic approaches. We analyzed 60 patients with advanced-stage, HGSC who survived more than 10 years after diagnosis using whole-genome sequencing, transcriptome, and methylome profiling of their primary tumor samples, comparing this data to 66 short- or moderate-term survivors. Tumors of long-term survivors were more likely to have multiple alterations in genes associated with DNA repair, and more frequent somatic variants resulting in an increased predicted neoantigen load. Patients clustered into survival groups based on genomic and immune cell signatures, including three subsets of patients with BRCA1 alterations with distinctly different outcomes. Specific combinations of germline and somatic gene alterations, tumor cell phenotypes, and differential immune responses appear to contribute to long-term survival in HGSC.
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001008537 | Illumina NovaSeq 6000 | 56 | |
EGAD00001009398 | HiSeq X Ten | 111 | |
EGAD00010002359 | Illumina Infinium OmniExpress-24 BeadChip array | 111 |
Publications | Citations |
---|---|
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.
Nat Genet 54: 2022 1853-1864 |
34 |
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
Clin Cancer Res 30: 2024 3481-3498 |
1 |